Levofloxacin, a fluoroquinolone antibiotic, can trigger false positives on certain drug screenings, primarily those targeting benzodiazepines. This is due to cross-reactivity in immunoassay tests. Understanding this potential pitfall is crucial for accurate interpretation of drug screening results.
Gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) provide definitive results and should be used to confirm any ambiguous findings. These methods offer superior specificity compared to initial screening immunoassays, mitigating the risk of misdiagnosis.
Clinicians should consider the patient’s medical history, including recent antibiotic use, when reviewing drug screen results. A thorough history, coupled with appropriate confirmatory testing, significantly reduces the likelihood of misinterpretation caused by levofloxacin interference.
Remember: Always consult updated clinical guidelines and laboratory procedures for the most accurate interpretation of drug screening results. A clear communication between the physician, the laboratory, and the patient is paramount for correct diagnosis and treatment. Documenting the potential for false positives due to levofloxacin is key for patient safety and legal compliance.
